Asthma is one of the most common chronic conditions of childhood and is associated with significant effect on quality of life. An ongoing controversy remains how to best treat asthma in children and adolescents. A provocative evolution in this controversy is the publication of new recommendations by the Global Initiative for Asthma (GINA), which present a significant change in asthma therapy.¹ Step 1 recommendations for mild asthma in adolescents 12 years and older and adults changed from as-needed short-acting β-agonist (SABA) to as-needed low-dose inhaled corticosteroid (ICS) formoterol (a long-acting β-agonist [LABA]). In children aged 6 to 11 years, GINA recommends that ICS therapy be used with SABA as needed or regular ICS with as-needed SABA as an alternative approach.

哮喘是儿童最常见的慢性疾病之一，对生活质量有重大影响。关于如何最好地治疗儿童和青少年哮喘仍存在争议。全球争议性哮喘病倡议（GINA）发布了新的建议，此争议中的一个令人鼓舞的进展是，该建议提出了哮喘治疗方面的重大变化。¹第¹步针对12岁及以上青少年的轻度哮喘的建议从需要的短效β受体激动剂（SABA）变为需要的低剂量吸入性糖皮质激素（ICS）福莫特罗（长效β受体激动剂[LABA]。对于6至11岁的儿童，GINA建议根据需要将ICS疗法与SABA一起使用，或者将常规ICS与需要的SABA一起作为替代方法。